ERBB3 Polyclonal antibody
ERBB3 Polyclonal Antibody for IHC, ELISA
Host / Isotype
Rabbit / IgG
Reactivity
human and More (1)
Applications
IHC, ELISA and More (1)
Conjugate
Unconjugated
验证数据展示
经过测试的应用
Positive IHC detected in | human breast cancer tissue, human prostate cancer tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
推荐稀释比
Application | Dilution |
---|---|
Immunohistochemistry (IHC) | IHC : 1:50-1:500 |
It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Sample-dependent, Check data in validation data gallery. |
发表文章中的应用
WB | See 8 publications below |
IHC | See 1 publications below |
产品信息
10369-1-AP targets ERBB3 in WB, IHC, ELISA applications and shows reactivity with human samples.
Tested Applications | IHC, ELISA Application Description |
Cited Applications | WB, IHC |
Tested Reactivity | human |
Cited Reactivity | human, mouse |
Immunogen | ERBB3 fusion protein Ag0215 种属同源性预测 |
Host / Isotype | Rabbit / IgG |
Class | Polyclonal |
Type | Antibody |
Full Name | v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian) |
Synonyms | c erbB 3, c erbB3, ErbB 3, ERBB3, erbB3 S, HER3, LCCS2, MDA BF 1, p180 ErbB3, p45 sErbB3, p85 sErbB3 |
Calculated Molecular Weight | 148 kDa |
GenBank Accession Number | BC002706 |
Gene Symbol | ERBB3 |
Gene ID (NCBI) | 2065 |
RRID | AB_2099548 |
Conjugate | Unconjugated |
Form | Liquid |
Purification Method | Antigen affinity purification |
UNIPROT ID | P21860 |
Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol pH 7.3. |
Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
背景介绍
实验方案
Product Specific Protocols | |
---|---|
IHC protocol for ERBB3 antibody 10369-1-AP | Download protocol |
Standard Protocols | |
---|---|
Click here to view our Standard Protocols |
发表文章
Species | Application | Title |
---|---|---|
Acta Pharmacol Sin Quantitative systems pharmacology modeling of HER2-positive metastatic breast cancer for translational efficacy evaluation and combination assessment across therapeutic modalities | ||
Cells NOX4 Signaling Mediates Cancer Development and Therapeutic Resistance through HER3 in Ovarian Cancer Cells. | ||
J Oncol CircEPSTI1 Promotes the Proliferation of HER2-Positive Breast Cancer Cells via circEPSTI1/miR-145/ERBB3 Axis | ||
Acta Otolaryngol ErbB1 and ErbB2 overexpression in patients with sinonasal inverted papilloma and inverted papilloma with squamous cell carcinoma in China. | ||
Cancers (Basel) Co-Targeting ErbB Receptors and the PI3K/AKT Axis in Androgen-Independent Taxane-Sensitive and Taxane-Resistant Human Prostate Cancer Cells |